Guggenheim Initiates Coverage On Solid Biosciences with Buy Rating, Announces Price Target of $26

Benzinga Newsdesk www.benzinga.com Neutral 54.1%

Neg 0% Neu 54.1% Pos 0%

Guggenheim analyst Debjit Chattopadhyay initiates coverage on Solid Biosciences (NASDAQ:SLDB) with a Buy rating and announces Price Target of $26.